A chrysin derivative suppresses skin cancer growth by inhibiting cyclin-dependent kinases

Journal of Biological Chemistry

Volumn 288, Issue 36, 2013, Pages 25924-25937

  Liu, Haidan ^a,b,c,d   Liu, Kangdong ^a,b,g   Huang, Zunnan ^b   Park, Chan Mi ^a   Thimmegowda, N R ^a   Jang, Jae Hyuk ^a   Ryoo, In Ja ^a   He, Long ^a   Kim, Sun Ok ^a   Oi, Naomi ^b   Lee, Ki Won ^e   Soung, Nak Kyun ^a   Bode, Ann M ^b   Yang, Yifeng ^c   Zhou, Xinmin ^c   Erikson, Raymond L ^f   Ahn, Jong Seog ^a   Hwang, Joonsung ^a   Kim, Kyoon Eon ^h   Dong, Zigang ^b   Kim, Bo Yeon ^a   more..

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e Seoul National University   (South Korea)

^f HARVARD UNIVERSITY   (United States)

^g ZHENGZHOU UNIVERSITY   (China)

^h Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERIC SITE; ANTICANCER ACTIVITIES; CHRYSIN; CYCLIN-DEPENDENT KINASE; PHARMACOPHORE MODELING; SKIN CANCERS;

BIOCHEMISTRY; BIOLOGY;

FLAVONOIDS;

ADENOSINE TRIPHOSPHATE; COMPOUND 69407; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR; FLAVONE DERIVATIVE; RETINOBLASTOMA PROTEIN; SERINE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STIMULATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ATP; ATP-NONCOMPETITIVE; CDK (CYCLIN-DEPENDENT KINASE); CDK INHIBITOR; CELL CYCLE; CHEMOPREVENTION; CHRYSIN DERIVATIVE; EPIDERMAL GROWTH FACTOR (EGF); NATURAL COMPOUND;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASES; EPIDERMAL GROWTH FACTOR; FLAVONOIDS; G1 PHASE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; RETINOBLASTOMA PROTEIN; S PHASE; SKIN NEOPLASMS;

EID: 84883735363     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.464669     Document Type: Article

References (56)

1. Lee, K. W., Kang, N. J., Heo, Y. S., Rogozin, E. A., Pugliese, A., Hwang, M. K., Bowden, G. T., Bode, A. M., Lee, H. J., and Dong, Z. (2008) Raf and MEKprotein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 68, 946-955
2. Kang, N. J., Lee, K. W., Lee, D. E., Rogozin, E. A., Bode, A. M., Lee, H. J., and Dong, Z. (2008) Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase kinase. J. Biol. Chem. 283, 20664-20673
3. Bode, A. M., Ma, W. Y., Surh, Y. J., and Dong, Z. (2001) Inhibition of epidermal growth factor-induced cell transformation and activator protein 1 activation by [6]-gingerol. Cancer Res. 61, 850-853
4. He, Z., Tang, F., Ermakova, S., Li, M., Zhao, Q., Cho, Y. Y., Ma, W. Y., Choi, H. S., Bode, A. M., Yang, C. S., and Dong, Z. (2008) Fyn is a novel target of -epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Mol. Carcinog. 47, 172-183
5. Bode, A. M., and Dong, Z. (2006) Molecular and cellular targets. Mol. Carcinog. 45, 422-430
6. Malumbres, M., and Barbacid, M. (2001) To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1, 222-231
7. Zou, X., Ray, D., Aziyu, A., Christov, K., Boiko, A. D., Gudkov, A. V., and Kiyokawa, H. (2002) Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 16, 2923-2934
8. Haas, K., Staller, P., Geisen, C., Bartek, J., Eilers, M., and Möröy, T. (1997) Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc. Oncogene 15, 179-192
9. Lazarov, M., Kubo, Y., Cai, T., Dajee, M., Tarutani, M., Lin, Q., Fang, M., Tao, S., Green, C. L., and Khavari, P. A. (2002) CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat. Med. 8, 1105-1114
10. Berthet, C., Aleem, E., Coppola, V., Tessarollo, L., and Kaldis, P. (2003) Cdk2 knockout mice are viable. Curr. Biol. 13, 1775-1785
11. Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., and Barbacid, M. (2003) Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35, 25-31
12. Sotillo, E., Garriga, J., Kurimchak, A., and Graña, X. (2008) Cyclin E and SV40 small T antigen cooperate to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts. J. Biol. Chem. 283, 11280-11292
13. Woo, K. J., Jeong, Y. J., Inoue, H., Park, J. W., and Kwon, T. K. (2005) Chrysin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression through the inhibition of nuclear factor for IL-6 (NF-IL6) DNAbinding activity. FEBS Lett. 579, 705-711
14. Zhang, T., Chen, X., Qu, L., Wu, J., Cui, R., and Zhao, Y. (2004) Chrysin and its phosphate ester inhibit cell proliferation and induce apoptosis in HeLa cells. Bioorg. Med. Chem. 12, 6097-6105
15. Galijatovic, A., Walle, U. K., and Walle, T. (2000) Induction of UDPglucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm. Res. 17, 21-26
16. Otake, Y., Hsieh, F., and Walle, T. (2002) Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes. Drug Metab. Dispos. 30, 576-581
17. Li, H. Q., Shi, L., Li, Q. S., Liu, P. G., Luo, Y., Zhao, J., and Zhu, H. L. (2009) Synthesis of C(7) modified chrysin derivatives designing to inhibit -ketoacyl- acyl carrier protein synthase III (FabH) as antibiotics. Bioorg. Med. Chem. 17, 6264-6269
18. Lv, P. C., Wang, K. R., Li, Q. S., Chen, J., Sun, J., and Zhu, H. L. (2010) Design, synthesis, and biological evaluation of chrysin long-chain derivatives as potential anticancer agents. Bioorg. Med. Chem. 18, 1117-1123
19. Zheng, X., Meng, W. D., Xu, Y. Y., Cao, J. G., and Qing, F. L. (2003) Synthesis and anticancer effect of chrysin derivatives. Bioorg. Med. Chem. Lett. 13, 881-884
20. Cheng, H., and Force, T. (2010) Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ. Res. 106, 21-34
21. Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., Mueller, W. T., Delaney, A., Omer, C., Sebolt-Leopold, J., Dudley, D. T., Leung, I. K., Flamme, C., Warmus, J., Kaufman, M., Barrett, S., Tecle, H., and Hasemann, C. A. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197
22. Lamba, V., and Ghosh, I. (2012) New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. Curr. Pharm. Des. 18, 2936-2945
23. Kim, D. J., Reddy, K., Kim, M. O., Li, Y., Nadas, J., Cho, Y. Y., Kim, J. E., Shim, J. H., Song, N. R., Carper, A., Lubet, R. A., Bode, A. M., and Dong, Z. (2011) (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer Prev. Res. 4, 1842-1851
24. Okram, B., Nagle, A., Adrián, F. J., Lee, C., Ren, P., Wang, X., Sim, T., Xie, Y., Wang, X., Xia, G., Spraggon, G., Warmuth, M., Liu, Y., and Gray, N. S. (2006) A general strategy for creating "inactive- conformation" abl inhibitors. Chem. Biol. 13, 779-786
25. Corsino, P., Horenstein, N., Ostrov, D., Rowe, T., Law, M., Barrett, A., Aslanidi, G., Cress, W. D., and Law, B. (2009) A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism. J. Biol. Chem. 284, 29945-29955
26. Betzi, S., Alam, R., Martin, M., Lubbers, D. J., Han, H., Jakkaraj, S. R., Georg, G. I., and Schönbrunn, E. (2011) Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol. 6, 492-501
27. Lee, D. E., Lee, K. W., Song, N. R., Seo, S. K., Heo, Y. S., Kang, N. J., Bode, A. M., Lee, H. J., and Dong, Z. (2010) 7,3,4-Trihydroxyisoflavone inhibits epidermal growth factor-induced proliferation and transformation of JB6 P mouse epidermal cells by suppressing cyclin-dependent kinases and phosphatidylinositol 3-kinase. J. Biol. Chem. 285, 21458-21466
28. Lun, X. Q., Zhou, H., Alain, T., Sun, B., Wang, L., Barrett, J. W., Stanford, M. M., McFadden, G., Bell, J., Senger, D. L., and Forsyth, P. A. (2007) Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 67, 8818-8827
29. Colburn, N. H., Wendel, E. J., and Abruzzo, G. (1981) Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc. Natl. Acad. Sci. U.S.A. 78, 6912-6916
30. Cho, Y. Y., Yao, K., Pugliese, A., Malakhova, M. L., Bode, A. M., and Dong, Z. (2009) A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. Cancer Res. 69, 4398-4406
31. Zheng, D., Cho, Y. Y., Lau, A. T., Zhang, J., Ma, W. Y., Bode, A. M., and Dong, Z. (2008) Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res. 68, 7650-7660
32. van den Heuvel, S., and Harlow, E. (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-2054
33. Friesner, R A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) Glide: a new approach for rapid, accurate docking and scoring Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749
34. Irwin, J. J., and Shoichet, B. K. (2005) ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177-182
35. Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., and Sherr, C. J. (1999) The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18, 1571-1583
36. Su, T. T., and Stumpff, J. (2004) Promiscuity rules? The dispensability of cyclin E and Cdk2. Sci. STKE 2004, pe11
37. Connell-Crowley, L., Harper, J. W., and Goodrich, D. W. (1997) Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 8, 287-301
38. Guo, J., Sheng, G., and Warner, B. W. (2005) Epidermal growth factorinduced rapid retinoblastoma phosphorylation at Ser-780 and Ser-795 is mediated by ERK1/2 in small intestine epithelial cells. J. Biol. Chem. 280, 35992-35998
39. Kitagawa, M., Higashi, H., Jung, H. K., Suzuki-Takahashi, I., Ikeda, M., Tamai, K., Kato, J., Segawa, K., Yoshida, E., Nishimura, S., and Taya, Y. (1996) The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15, 7060-7069
40. Brugarolas, J., Moberg, K., Boyd, S. D., Taya, Y., Jacks, T., and Lees, J. A. (1999) Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after -irradiation. Proc. Natl. Acad. Sci. U.S.A. 96, 1002-1007
41. Tetsu, O., and McCormick, F. (2003) Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3, 233-245
42. Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G., and Moulinoux, J. P. (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclindependent kinases cdc2, cdk2, and cdk5. Eur. J. Biochem. 243, 527-536
43. Ali, S., Heathcote, D. A., Kroll, S. H., Jogalekar, A. S., Scheiper, B., Patel, H., Brackow, J., Siwicka, A., Fuchter, M. J., Periyasamy, M., Tolhurst, R. S., Kanneganti, S. K., Snyder, J. P., Liotta, D. C., Aboagye, E. O., Barrett, A. G., and Coombes, R. C. (2009) The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 69, 6208-6215
44. Mizuno, H., Cho, Y. Y., Ma, W. Y., Bode, A. M., and Dong, Z. (2006) Effects of MAP kinase inhibitors on epidermal growth factor-induced neoplastic transformation of human keratinocytes. Mol. Carcinog. 45, 1-9
45. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53, 4637-4642
46. Morgan, D. O. (1995) Principles of CDK regulation. Nature 374, 131-134
47. Sherr, C. J. (1993) Mammalian G1 cyclins. Cell 73, 1059-1065
48. Dyson, N. (1998) The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245-2262
49. Huet, X., Rech, J., Plet, A., Vié, A., and Blanchard, J. M. (1996) Cyclin A expression is under negative transcriptional control during the cell cycle. Mol. Cell. Biol. 16, 3789-3798
50. Royzman, I., Whittaker, A. J., and Orr-Weaver, T. L. (1997) Mutations in Drosophila DP and E2F distinguish G1-S progression from an associated transcriptional program. Genes Dev. 11, 1999-2011
51. Zhu, W., Giangrande, P. H., and Nevins, J. R. (2004) E2Fs link the control of G1/S and G2/M transcription. EMBO J. 23, 4615-4626
52. Nguyen, V. Q., Co, C., and Li, J. J. (2001) Cyclin-dependent kinases prevent DNA re-replication through multiple mechanisms. Nature 411, 1068-1073
53. Vaziri, C., Saxena, S., Jeon, Y., Lee, C., Murata, K., Machida, Y., Wagle, N., Hwang, D. S., and Dutta, A. (2003) A p53-dependent checkpoint pathway prevents re-replication. Mol. Cell 11, 997-1008
54. Malumbres, M., Pevarello, P., Barbacid, M., and Bischoff, J. R. (2008) CDK inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci. 29, 16-21
55. Lee, K. W., Kang, N. J., Rogozin, E. A., Oh, S. M., Heo, Y. S., Pugliese, A., Bode, A. M., Lee, H. J., and Dong, Z. (2008) The resveratrol analogue 3,5,3,4,5-pentahydroxy-trans-stilbene inhibits cell transformation via MEK. Int. J. Cancer 123, 2487-2496
56. Lee, K. W., Bode, A. M., and Dong, Z. (2011) Molecular targets of phytochemicals for cancer prevention. Nat. Rev. Cancer 11, 211-218